Related posts
Nervous markets await NvidiaThis summary was created by AI, based on 6 opinions in the last 12 months.
Viatris (VTRS-Q) has been a mixed bag for investors. While the stock has experienced a significant drop of around 15% following weak earnings, it is generating substantial free cash flow, which should be redirected towards share buybacks at an attractive valuation. Analysts emphasize the stock’s low price-to-earnings ratio of around 5x, suggesting it is quite cheap, with some experts predicting a target price of $20. Despite its challenges, including an investigation affecting an EBITDA of $300-400M, the 4% dividend yield offers stability. With a market cap of $12B, the company is seen as under-researched and is pursuing multiple avenues such as debt reduction, acquisitions, and share repurchases.
It is the cheapest stock in their portfolio at 4X earnings, a pharma company formed by a joint venture. Its investment grade bond issues are in rock solid shape. It sold a division for $2 billion and will use the cash for a couple of acquisitions in eye wear and to buy back stock. There are potential sales of other smaller divisions so there could be more buybacks plus paying down debt. The dividend yield is 4.1%. Has a low price due to a couple of disappointing quarters but numbers have been solid since. Also revenues have been flat-lining.
Buy 4 Hold 10 Sell 0
Viatris is a American stock, trading under the symbol VTRS-Q on the NASDAQ (VTRS). It is usually referred to as NASDAQ:VTRS or VTRS-Q
In the last year, 9 stock analysts published opinions about VTRS-Q. 3 analysts recommended to BUY the stock. 3 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Viatris.
Viatris was recommended as a Top Pick by on . Read the latest stock experts ratings for Viatris.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
9 stock analysts on Stockchase covered Viatris In the last year. It is a trending stock that is worth watching.
On 2025-04-25, Viatris (VTRS-Q) stock closed at a price of $8.13.
Proof that not every stock he buys goes up ;) He's held for years. Recent earnings were weak, and stock fell ~15%. Generating significant free cashflow, which now will be used to buy back shares incredibly cheaply. It's the best use of capital at this time. FDA investigation in one of their plants, costing about $300-400M in EBITDA. Yield is 4+%.